Add this topic to your myFT Digest for news straight to your inbox
US group snaps up UK maker of marijuana-based epilepsy drug as sector interest grows
Investors in a pioneering fund should brace themselves for a rollercoaster ride
There will be more cannabinoid-related patents and profits to come
GW Pharmaceuticals said regulators could approve Epidiolex as early as this week
Nation known for its tech start-ups is tapping a new field for growth
News that experimental treatment cut the number of seizures propels stocks higher
UK stocks slip as results dominate in the wider market
Trial results for Epidiolex crucial for GW Pharma — first British company to test cannabinoid market
Largest portfolio of privately owned sites bought by US private equity company
US markets stronger after positive consumer data report
Equity markets and venture capital raise hopes of narrowing gap with US biotech sector
Share placement shows renewed appetite in sector where Shire’s success has been the exception
Investors including Invesco and Neil Woodford support share offering by anti-allergy specialist
Oil and hand cream products use hemp from Czech Republic
SkyePharma, Xeros, Naibu and Focusrite featured
GW Pharmaceuticals aims to raise funding on Nasdaq for anti-epilepsy treatment
International Edition